Advertisement

CD44 and Primary Open Angle Glaucoma

  • Paul A. Knepper
  • Michael J. Nolan
  • Beatrice Y. J. T. Yue
Chapter

Abstract

In our view, primary open-angle glaucoma (POAG) is a common neurodegenerative disease caused by a variety of molecular defects and/or cellular insults that result in cell stress and death of the trabecular meshwork (TM) and retinal ganglion cells (RGC). One potential biological marker of POAG is CD44, which is one of the adhesion/homing molecules. Direct evidence for CD44’s very central role in POAG includes: (1) aqueous humor of patients with POAG contains an increased amount of the soluble extracellular 32-kDa fragment of CD44 (sCD44) in comparison with the aqueous humor of age-matched normal individuals; (2) increased levels of sCD44 in the aqueous correlates with the extent of visual field loss in POAG patients; (3) sCD44, particularly hypo-phosphorylated sCD44, is a potent and specific toxic protein to TM and RGC in vitro; and (4) overexpression of both full-length CD44 and truncated sCD44 in transgenic mouse eyes is sufficient to cause ocular hypertension. The increase in intraocular pressure (IOP) lasted more than 90 days accompanied by optic nerve damage. The overexpression of CD44 may thus be the first documented animal model that closely mimics the human disease POAG. Other models have been cytodestructive and nonphysiologic.

Keywords

Hyaluronic Acid Aqueous Humor Trabecular Meshwork Visual Field Loss Retinal Ganglion Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Knepper PA, Mayanil CSK, Goossens W, et al. Aqueous humor in primary open-angle glaucoma contains an increased level of CD44S. Invest Ophthalmol Vis Sci. 2002;343:133–139.Google Scholar
  2. 2.
    Nolan MJ, Giovingo MC, Miller AM, et al. Influence of race on visual field loss and aqueous humor soluble CD44 concentration in primary open-angle glaucoma. J Glaucoma. 2007;16:419–429.CrossRefPubMedGoogle Scholar
  3. 3.
    Choi J, Miller AM, Nolan MJ, et al. Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci. 2005;46:214–222.CrossRefPubMedGoogle Scholar
  4. 4.
    Shepard AR, Nolan MJ, Millar JC, et al. CD44 Overexpression Causes Ocular Hypertension in the Mouse. ARVO annual meeting; 2008Google Scholar
  5. 5.
    Knepper PA, Goossens W, Palmberg PF. Glycosaminoglycan profile of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1996;37:1360–1367.PubMedGoogle Scholar
  6. 6.
    Knepper PA, Goossens W, Palmberg PF. Glycosaminoglycan stratification in normal and primary open-angle glaucoma juxtacanalicular tissue. Invest Ophthalmol Vis Sci. 1996;37:2414–2425.PubMedGoogle Scholar
  7. 7.
    Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem. 2002;277:4581–4584.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol. 2000;12:581–586.CrossRefPubMedGoogle Scholar
  9. 9.
    Gong H, Ye W, Freddo TF, Hernandez MR. Hyaluronic acid in the normal and glaucomatous optic nerve. Exp Eye Res. 1997;64:587–595.CrossRefPubMedGoogle Scholar
  10. 10.
    Toole BP. Hyaluronan is not just a goo! J Clin Invest. 2000;106:335–338.CrossRefPubMedGoogle Scholar
  11. 11.
    Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585–4588.CrossRefPubMedGoogle Scholar
  12. 12.
    Knepper PA, Lukas R, Wills J, Goossens W, Mayanil CSK. Hyaluronic acid receptors of the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1997;38:S451.Google Scholar
  13. 13.
    Gunthert U, Johansson B. CD44-a protein family involved in autoimmune diseases and apoptosis. Immunologist. 2001;8:4–5.Google Scholar
  14. 14.
    Lokeshwar VB, Iida N, Bourguignon LY. The cell adhesion molecule, GP116, is a new CD44 variant (ex4/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem. 1996;271:23853–23864.CrossRefPubMedGoogle Scholar
  15. 15.
    Gunthert U. CD44 in malignant disorders. Curr Top Microbiol Immunol. 1996;213:271–285.PubMedGoogle Scholar
  16. 16.
    Gee K, Kryworuchko M, Kumar A. Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2004;52:13–26.Google Scholar
  17. 17.
    Naor D, Nedvetzki S, Walmsley M, et al. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci. 2007;1110:233–247.CrossRefPubMedGoogle Scholar
  18. 18.
    Eshkar Sebban L, Ronen D, Levartovsky D, et al. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol. 2007;179:1225–1235.PubMedGoogle Scholar
  19. 19.
    Vachon E, Martin R, Plumb J, et al. CD44 is a phagocytic receptor. Blood. 2006;107:4149–4158.CrossRefPubMedGoogle Scholar
  20. 20.
    Vachon E, Martin R, Kwok V, et al. CD44-mediated phagocytosis induces inside-out activation of complement receptor-3 in murine macrophages. Blood. 2007;110:4492–4502.CrossRefPubMedGoogle Scholar
  21. 21.
    Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. 2002;277:38013–38020.CrossRefPubMedGoogle Scholar
  22. 22.
    Singleton PA, Salgia R, Moreno-Vinasco L, et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007;282:30643–30657.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang M, Wang MH, Singh RK, Wells A, Siegal GP. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem. 1997;272:14139–14146.CrossRefPubMedGoogle Scholar
  24. 24.
    Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr Med Assoc J. 2008;10:20–25.PubMedGoogle Scholar
  25. 25.
    Garin T, Rubinstein A, Grigoriadis N, et al. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neuro Sci. 2007;258:17–26.CrossRefGoogle Scholar
  26. 26.
    Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med. 1997;186:1985–1996.CrossRefPubMedGoogle Scholar
  27. 27.
    Cichy J, Pure E. The liberation of CD44. J Cell Biol. 2003;161:839–843.CrossRefPubMedGoogle Scholar
  28. 28.
    Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893–904.CrossRefPubMedGoogle Scholar
  29. 29.
    Lesley J, Hyman R. CD44 structure and function. Front Biosci. 1998;1:616–630.Google Scholar
  30. 30.
    Kincade PW, Zheng Z, Katoh S, Hanson L. The importance of cellular environment to function of the CD44 matrix receptor. Curr Opin Cell Biol. 1997;9:635–642.CrossRefPubMedGoogle Scholar
  31. 31.
    Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol. 2002;34:718–721.CrossRefPubMedGoogle Scholar
  32. 32.
    Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008 [Epub ahead of print]Google Scholar
  33. 33.
    Toyama-Sorimachi N, Miyasaka M. A sulfated proteoglycan as a novel ligand for CD44. J Dermatol. 1994;21:795–801.PubMedGoogle Scholar
  34. 34.
    Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol. 1992;116:817–825.CrossRefPubMedGoogle Scholar
  35. 35.
    Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509–512.CrossRefPubMedGoogle Scholar
  36. 36.
    Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. J Cell Biol. 1998;8:438–442.Google Scholar
  37. 37.
    Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998;39:2514–2516.PubMedGoogle Scholar
  38. 38.
    Bradley JMB, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649–2658.PubMedGoogle Scholar
  39. 39.
    Sherman L, Sleeman J, Dall P, et al. The CD44 proteins in embryonic development and in cancer. Curr Top Microbiol Immunol. 1996;213:249–269.PubMedGoogle Scholar
  40. 40.
    Tsukita A, Oishi K, Sato N, et al. ERM family members are molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeleton. J Cell Biol. 1994;126:391–401.CrossRefPubMedGoogle Scholar
  41. 41.
    Jiang H, Peterson RS, Wang W, et al. A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells. J Biol Chem. 2002;277:10531–10533.CrossRefPubMedGoogle Scholar
  42. 42.
    Sretavan DW, Feng L, Pure E, Reichardt LF. Embryonic neurons of the developing optic chiasm express L1 and CD44, cell surface molecules with opposing effects on retinal axon growth. Neuron. 1994;12:957–975.CrossRefPubMedGoogle Scholar
  43. 43.
    Flurkey K, Stadecker M, Miller RA. Memory T lymphocyte hyporesponsiveness to noncognate stimuli: a key factor in age-related immunodeficiency. Eur J Immunol. 1992;2:931–935.CrossRefGoogle Scholar
  44. 44.
    Hirano F, Hirano H, Hino E, et al. CD44 isoform expression in periodontal tissues: cell-type specific regulation of alternative splicing. J Periodontal Res. 1997;32:634–645.CrossRefPubMedGoogle Scholar
  45. 45.
    Naot D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.CrossRefGoogle Scholar
  46. 46.
    Liu N, Xu XM, Chen J, et al. Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2. Int J Cancer. 2004;109:49–57.CrossRefPubMedGoogle Scholar
  47. 47.
    Knepper PA, Koga T, Nolan M, Yue BYJT, Sheppard A, Clark A. Multidrug resistance proteins and trabecular meshwork. ARVO annual meeting; 2007Google Scholar
  48. 48.
    Knepper PA, Goossens W, Mayanil CSK. CD44 localization in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1998;39:673–680.PubMedGoogle Scholar
  49. 49.
    Camp RL, Krauss TA, Pure E. Variations in the cytoskeletal interaction and posttranslational modifications of the CD44 homing receptor in macrophages. J Cell Biol. 1991;115:1283–1292.CrossRefPubMedGoogle Scholar
  50. 50.
    Lesley J, English N, Perschl A, et al. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med. 1995;182:431–437.CrossRefPubMedGoogle Scholar
  51. 51.
    Thankamony SP, Knudson W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J Biol Chem. 2006;281:34601–34609.CrossRefPubMedGoogle Scholar
  52. 52.
    Seiki M. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol. 2002;14:624–632.CrossRefPubMedGoogle Scholar
  53. 53.
    Stoeck A, Keller S, Riedle S, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006;393:609–618.CrossRefPubMedGoogle Scholar
  54. 54.
    Yang P, Baker KA, Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol. 2006;79:73–94.CrossRefPubMedGoogle Scholar
  55. 55.
    Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem. 2002;277:44754–44759.CrossRefPubMedGoogle Scholar
  56. 56.
    Liu F, Su Y, Li B, et al. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003;547:193–196.CrossRefPubMedGoogle Scholar
  57. 57.
    Tamura H, Kawakami H, Kanamoto T, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci. 2006;246:79–83.CrossRefPubMedGoogle Scholar
  58. 58.
    Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol. 2002;47:165–168.CrossRefPubMedGoogle Scholar
  59. 59.
    Rajendran L, Schneider A, Schlechtingen G, et al. Efficient inhibition of the Alzheimer’s disease beta-secretase by membrane targeting. Science. 2008;320:520–523.CrossRefPubMedGoogle Scholar
  60. 60.
    Tesco G, Koh YH, Kang EL, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54:721–737.CrossRefPubMedGoogle Scholar
  61. 61.
    Werb Z, Yan Y. A cellular striptease act. Science. 1998;282:1279–1280.CrossRefPubMedGoogle Scholar
  62. 62.
    Lee MC, Alpaugh ML, Nguyen M, et al. Myoepithelial-specific CD44 shedding is mediated by a putative chymotrypsin-like sheddase. Biochem Biophys Res Commun. 2000;279:116–123.CrossRefPubMedGoogle Scholar
  63. 63.
    Li HL, Wang HH, Liu SJ, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Nat Acad Sci U S A. 2007;104:3591–3596.CrossRefGoogle Scholar
  64. 64.
    Knepper PA, Miller AM, Choi J, et al. Hypo-phosphorylation of aqueous humor sCD44 and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:2829–2837.CrossRefPubMedGoogle Scholar
  65. 65.
    Giovingo MC, Nolan MJ, Koga T, et al. Aqueous humor sCD44 concentration in Diabetes and Primary Open-Angle Glaucoma. ARVO annual meeting; 2008Google Scholar
  66. 66.
    Cavin LG, Romieu-Mourez R, Panta GR, et al. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology. 2003;38:1540–1551.PubMedGoogle Scholar
  67. 67.
    Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723–727.CrossRefPubMedGoogle Scholar
  68. 68.
    Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118:1056–1064.PubMedGoogle Scholar
  69. 69.
    Chen HK, Fernandez-Funez P, Acevedo SF, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003;113:457–468.CrossRefPubMedGoogle Scholar
  70. 70.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657.CrossRefPubMedGoogle Scholar
  71. 71.
    Wei W, Wang X, Kusiak JW. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem. 2002;277:17649–17656.CrossRefPubMedGoogle Scholar
  72. 72.
    Sherman LS, Rizvi TA, Karyala S, Ratner N. CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol. 2000;150:1071–1084.CrossRefPubMedGoogle Scholar
  73. 73.
    Suo Z, Risberg B, Karlsson MG, et al. The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol. 2002;10:91–99.CrossRefPubMedGoogle Scholar
  74. 74.
    Alexander JP, Acott TS. Involvement of protein kinase C in TNF alpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2001;42:2831–2838.PubMedGoogle Scholar
  75. 75.
    Limb GA, Daniels JT, Pleass R, et al. Differential expression of matrix metalloproteinases 2 and 9 by glial Muller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha. Am J Pathol. 2002;160:1847–1855.PubMedGoogle Scholar
  76. 76.
    Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716–722.PubMedGoogle Scholar
  77. 77.
    OH J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107:789–800.CrossRefPubMedGoogle Scholar
  78. 78.
    Xu XM, Chen Y, Chen J, et al. A peptide with three hyaluronan binding motifs inhibits tumor growth and inducesapoptosis. Cancer Res. 2003;63:5685–5690.PubMedGoogle Scholar
  79. 79.
    Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med. 1992;176:623–637.CrossRefPubMedGoogle Scholar
  80. 80.
    Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med. 1996;183:1663–1668.CrossRefPubMedGoogle Scholar
  81. 81.
    Wisniewski HG, Naime D, Hua JC, Vilcek J, Cronstein BN. TSG-6, a glycoprotein associated with arthritis, and its ligand hyaluronan exert opposite effects in a murine model of inflammation. Pflugers Arch. 1996;431(6 Suppl 2):R225-R226.CrossRefPubMedGoogle Scholar
  82. 82.
    Rubinstein DB, Stortchevoi A, Boosalis M, et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer. 2004;110:741–750.CrossRefPubMedGoogle Scholar
  83. 83.
    Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001;61:1022–1028.PubMedGoogle Scholar
  84. 84.
    Yu Q, Toole BP. A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem. 1996;271:20603–20607.CrossRefPubMedGoogle Scholar
  85. 85.
    Zeng CX, Toole BP, Kinney SD, Kuo JW, Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer. 1998;77:396–401.CrossRefPubMedGoogle Scholar
  86. 86.
    Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;7:304–309.CrossRefPubMedGoogle Scholar
  87. 87.
    Fitzgerald KA, Bowie AG, Skeffington BS, O'Neill LA. Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NFkappa B by hyaluronic acid fragments in T-24 carcinoma cells. J Immunol. 2000;164:2053–2063.PubMedGoogle Scholar
  88. 88.
    Miller AM, Nolan MJ, Choi J, et al. Lactate treatment causes NK-κB activation and CD44 shedding in cultured trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007;48:1615–1621.CrossRefPubMedGoogle Scholar
  89. 89.
    Schwamborn K, Weil R, Courtois G, Whiteside ST, Israel A. Phorbol esters and cytokines regulate the expression of the NEMO-related protein, a molecule involved in a NF-kappa B-independent pathway. J Biol Chem. 2000;275:22780–22788.CrossRefPubMedGoogle Scholar
  90. 90.
    Stern R, Shuster S, Neudecker BA, Formby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res. 2002;276:24–31.CrossRefPubMedGoogle Scholar
  91. 91.
    Pache M, Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol. 2006;51:179–212.CrossRefPubMedGoogle Scholar
  92. 92.
    Wang WH, McNatt LG, Pang IH, et al. Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure. Invest Ophthalmol Vis Sci. 2008;49:1916–1923.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Paul A. Knepper
    • 1
  • Michael J. Nolan
    • 1
  • Beatrice Y. J. T. Yue
    • 1
  1. 1.Department of Ophthalmology and Visual ScienceUniversity of IllinoisChicagoUSA

Personalised recommendations